Literature DB >> 2365191

Epidemiology of irritable bowel syndrome in the United States.

R S Sandler1.   

Abstract

Data from six large, systematic national health surveys were examined to provide a more complete description of the epidemiology of irritable bowel syndrome in the United States. Data from the Second National Health and Nutrition Examination Survey, 1976-1980, indicated 4.7 million people (2.9% of the population) with self-reported diagnoses of irritable bowel syndrome. Rates for women were 3.2 times those for men, and rates for whites were 5.3 times those for blacks. Rates were highest among those aged 45-64 years. More than 2.6 million (1.6% of the population) were symptomatic at the time of the survey. Data from the National Ambulatory Medical Care Survey, 1985, and the National Disease and Therapeutic Index, 1987, documented between 2.4 and 3.5 million yearly visits to physicians by patients with irritable bowel syndrome and more than 2.2 million medications prescribed. Rates of hospitalization for women have fallen from 71.9 (per 100,000 population) in 1982 to 21.1 in 1987 based on data from the National Hospital Discharge Survey. A similar pattern was observed in data from the Commission on Professional and Hospital Activities. The data support the impression that irritable bowel syndrome is a prevalent condition in the United States with significant impact on health care. Large-scale, population-based surveys using standard criteria are needed to estimate the true extent of irritable bowel syndrome.

Entities:  

Mesh:

Year:  1990        PMID: 2365191     DOI: 10.1016/0016-5085(90)91023-y

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  60 in total

1.  Sex and age differences in the pharmacokinetics of alosetron.

Authors:  K M Koch; J L Palmer; N Noordin; J J Tomlinson; C Baidoo
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  Identifying and managing patients at low risk of bowel cancer in general practice.

Authors:  M R Thompson; I Heath; B G Ellis; E T Swarbrick; L Faulds Wood; W S Atkin
Journal:  BMJ       Date:  2003-08-02

3.  Diagnosing irritable bowel syndrome: what's too much, what's enough?

Authors:  Susan Lucak
Journal:  MedGenMed       Date:  2004-03-12

4.  Familial aggregation of irritable bowel syndrome: a family case-control study.

Authors:  Yuri A Saito; Gloria M Petersen; Joseph J Larson; Elizabeth J Atkinson; Brooke L Fridley; Mariza de Andrade; G Richard Locke; Janice M Zimmerman; Ann E Almazar-Elder; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2010-03-16       Impact factor: 10.864

5.  Is health care seeking for irritable bowel syndrome and functional dyspepsia a socially learned response to illness?

Authors:  Natasha A Koloski; Philip M Boyce; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

6.  Effects of fasting therapy on irritable bowel syndrome.

Authors:  Motoyori Kanazawa; Shin Fukudo
Journal:  Int J Behav Med       Date:  2006

7.  Assessment of functional gastrointestinal disorders using the Gastro-Questionnaire.

Authors:  Rolf Leibbrand; Ulrich Cuntz; Wolfgang Hiller
Journal:  Int J Behav Med       Date:  2002

8.  Conditioned pain modulation in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert J Shulman; Kevin C Cain; Wimon Deechakawan; Lynne T Smith; Philippe Richebé; Margaret Eugenio; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2014-01-24       Impact factor: 2.522

9.  Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria.

Authors:  Xavier Badia; Fermin Mearin; Agustin Balboa; Eva Baró; Ellen Caldwell; Mercedes Cucala; Manuel Díaz-Rubio; Arturo Fueyo; Julio Ponce; Mentse Roset; Nicholas J Talley
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 10.  New insights into the psychosocial aspects of irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.